|Dr. William K. Heiden||CEO & Director||1.18M||N/A||58|
|Mr. Edward H. Myles MBA||Exec. VP & CFO||434.9k||N/A||46|
|Mr. Joseph D. Vittiglio Esq.||Exec. VP of Quality, Gen. Counsel & Sec.||528.06k||N/A||46|
|Dr. Julie Krop M.D.||Exec. VP & Chief Medical Officer||567.37k||N/A||52|
|Mr. Nicholas Grund||Exec. VP & Chief Commercial Officer||772.39k||N/A||48|
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
AMAG Pharmaceuticals, Inc.’s ISS Governance QualityScore as of January 1, 2018 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 1; Compensation: 5.